Deals in Depth: January 2010
Alliance dollars were low in January, with only three biopharma deals reaching a potential deal value of $100 million or more, led by Ipsen and Inspiration's collaboration in hemophilia, worth $518 million. The bigger M&A dollars were seen in the device and diagnostic sectors, including Medtronic's take-out of CV device firm Invatec and its affiliates for $500 million. Both biopharma and device financing were down compared with December.
You may also be interested in...
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.
C&D CEO Matthew Farrell says Zicam has 73% share in the US zinc-containing wellness product market. It's acquiring marketer Matrixx Initiatives at a price almost 15 times Zicam brand’s projected 2021 EBITDA.
ChromaDex is among latest targets of FDA/FTC joint warnings identifying claims on websites as well as in social media posts that render products unapproved and misbranded drugs indicated to prevent or treat COVID-19.